Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 30 07 2020
accepted: 10 11 2020
entrez: 23 11 2020
pubmed: 24 11 2020
medline: 15 12 2020
Statut: epublish

Résumé

Despite evidence of socio-demographic disparities in outcomes of COVID-19, little is known about characteristics and clinical outcomes of patients admitted to public hospitals during the COVID-19 outbreak. To assess demographics, comorbid conditions, and clinical factors associated with critical illness and mortality among patients diagnosed with COVID-19 at a public hospital in New York City (NYC) during the first month of the COVID-19 outbreak. Retrospective chart review of patients diagnosed with COVID-19 admitted to NYC Health + Hospitals / Bellevue Hospital from March 9th to April 8th, 2020. A total of 337 patients were diagnosed with COVID-19 during the study period. Primary analyses were conducted among those requiring supplemental oxygen (n = 270); half of these patients (135) were admitted to the intensive care unit (ICU). A majority were male (67.4%) and the median age was 58 years. Approximately one-third (32.6%) of hypoxic patients managed outside the ICU required non-rebreather or non-invasive ventilation. Requirement of renal replacement therapy occurred in 42.3% of ICU patients without baseline end-stage renal disease. Overall, 30-day mortality among hypoxic patients was 28.9% (53.3% in the ICU, 4.4% outside the ICU). In adjusted analyses, risk factors associated with mortality included dementia (adjusted risk ratio (aRR) 2.11 95%CI 1.50-2.96), age 65 or older (aRR 1.97, 95%CI 1.31-2.95), obesity (aRR 1.37, 95%CI 1.07-1.74), and male sex (aRR 1.32, 95%CI 1.04-1.70). COVID-19 demonstrated severe morbidity and mortality in critically ill patients. Modifications in care delivery outside the ICU allowed the hospital to effectively care for a surge of critically ill and severely hypoxic patients.

Sections du résumé

BACKGROUND
Despite evidence of socio-demographic disparities in outcomes of COVID-19, little is known about characteristics and clinical outcomes of patients admitted to public hospitals during the COVID-19 outbreak.
OBJECTIVE
To assess demographics, comorbid conditions, and clinical factors associated with critical illness and mortality among patients diagnosed with COVID-19 at a public hospital in New York City (NYC) during the first month of the COVID-19 outbreak.
DESIGN
Retrospective chart review of patients diagnosed with COVID-19 admitted to NYC Health + Hospitals / Bellevue Hospital from March 9th to April 8th, 2020.
RESULTS
A total of 337 patients were diagnosed with COVID-19 during the study period. Primary analyses were conducted among those requiring supplemental oxygen (n = 270); half of these patients (135) were admitted to the intensive care unit (ICU). A majority were male (67.4%) and the median age was 58 years. Approximately one-third (32.6%) of hypoxic patients managed outside the ICU required non-rebreather or non-invasive ventilation. Requirement of renal replacement therapy occurred in 42.3% of ICU patients without baseline end-stage renal disease. Overall, 30-day mortality among hypoxic patients was 28.9% (53.3% in the ICU, 4.4% outside the ICU). In adjusted analyses, risk factors associated with mortality included dementia (adjusted risk ratio (aRR) 2.11 95%CI 1.50-2.96), age 65 or older (aRR 1.97, 95%CI 1.31-2.95), obesity (aRR 1.37, 95%CI 1.07-1.74), and male sex (aRR 1.32, 95%CI 1.04-1.70).
CONCLUSION
COVID-19 demonstrated severe morbidity and mortality in critically ill patients. Modifications in care delivery outside the ICU allowed the hospital to effectively care for a surge of critically ill and severely hypoxic patients.

Identifiants

pubmed: 33227019
doi: 10.1371/journal.pone.0242760
pii: PONE-D-20-23829
pmc: PMC7682848
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0242760

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Am Soc Nephrol. 2020 Aug;31(8):1683-1687
pubmed: 32371536
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nephron. 2020;144(5):213-221
pubmed: 32203970
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
Lancet Rheumatol. 2020 Oct;2(10):e592
pubmed: 32929415
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
BMJ. 2020 May 22;369:m1923
pubmed: 32444358
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):603-605
pubmed: 32407306
BMJ. 2020 Apr 21;369:m1588
pubmed: 32317305
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin J Am Soc Nephrol. 2020 Jun 8;15(6):880-882
pubmed: 32345750
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Dement Geriatr Cogn Disord. 2015;39(1-2):52-67
pubmed: 25342272
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
BMJ. 2020 May 22;369:m1985
pubmed: 32444460

Auteurs

Thomas D Filardo (TD)

Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, United States of America.

Maria R Khan (MR)

Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States of America.

Noa Krawczyk (N)

Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States of America.

Hayley Galitzer (H)

New York University Grossman School of Medicine, New York, NY, United States of America.

Savannah Karmen-Tuohy (S)

New York University Grossman School of Medicine, New York, NY, United States of America.

Megan Coffee (M)

Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, United States of America.
NYC Health + Hospitals, Bellevue Hospital Center, New York, NY, United States of America.

Verity E Schaye (VE)

NYC Health + Hospitals, Bellevue Hospital Center, New York, NY, United States of America.
Department of Medicine, New York University Grossman School of Medicine, New York, NY, United States of America.

Benjamin J Eckhardt (BJ)

Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, United States of America.
NYC Health + Hospitals, Bellevue Hospital Center, New York, NY, United States of America.

Gabriel M Cohen (GM)

Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY, United States of America.
NYC Health + Hospitals, Bellevue Hospital Center, New York, NY, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH